# Epigenic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epigenic

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.epigenictx.com
- Total disclosed funding: $92M
- Latest round: Series B (Sep 7, 2025)
- Investors on record: 5

## About

Established in 2021 and based in Shanghai, China, EPI Genic operates as a biotechnology company committed to developing next-generation gene editing therapy by regulation of epigenetic genomes. In August 2023, EPI Genic raised USD 32 million in series A funding co-led by new investors OrbiMed Advisors and Qiming Venture Partners, with participation from returning investor 5Y Captial. In September 2025, EPI Genic raised USD 60 million in series B funding led by new investor Lapam Capital, with participation from returning investors Qiming Venture Partners and OrbiMed Advisors, and other unspecified investors.

The company is committed to using its epigenetic regulation technology to treat a wide range of diseases. Its proprietary technology platform is explored through artificial intelligence (AI) algorithms, which can obtain CRISPR-Cas components that regulate target genes or manipulate the expression of multiple genes simultaneously without altering the DNA sequence. Combined with the company's Lipid Nanoparticle (LNP) drug delivery system, the company's technology platform has been validated in in-vivo and in-vitro models of ocular, neurological, metabolic, and rare diseases to deliver drugs precisely and to target cells and tissues. It also has multiple pipeline product candidates in place covering metabolic, cardiovascular, viral hepatitis, ophthalmology and rare diseases.

The company generates revenue from providing gene editing therapy solutions. 

The series B funding will primarily support the continued clinical development of the innovative epigenetic drug EPI-003 for the clinical cure of chronic hepatitis B and EPI-001 for the treatment of hypercholesterolemia. It will be also used by the company to rapidly advance multiple preclinical projects and continuously build technology platforms.

## Funding rounds

- Series B, Sep 7, 2025, $60M — OrbiMed Advisors, Qiming Venture Partners, Lapam Capital
- Series A, Aug 30, 2023, $32M — OrbiMed Advisors, Qiming Venture Partners, 5Y Capital
- Angel, May 9, 2022 — FountainBridge Capital

## Investors

- FountainBridge Capital (https://capitalatlas.ai/funds/fountainbridge-capital) — Angel
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series B